Short-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjects

TMC278 showed antiviral activity when given as monotherapy for 7 days at all doses studied and the drug was safe and well tolerated. Trials of longer treatment duration with TMC278, in combination with other antiretroviral drugs, are underway to assess the long-term durability of antiviral response, safety and tolerability.